title: [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
abstract: OBJECTIVE
  Androgen deprivation therapy (ADT) in patients with prostate cancer is associated with bone loss. We investigated the effectiveness of risedronate about a decreasing bone mineral density in patients with prostate cancer on ADT.
  
  
  METHODS
  A prospective study was conducted in Kitasato University Hospital from April 2004 to October 2006. A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve). The treatment group was 58 men and taking 2.5 mg risedronate per day. The control group was 11 men. At baseline, we assessed BMD (bone mineral density) by DEXA and urinary NTX, and measured for these changes every 6 months.
  
  
  RESULTS
  At baseline, each BMDs had no significant difference at the lumber and total hip. At the first 6-month stage, the change in BMD percentage between the 2 groups was statistically significantly different at lumber (p = 0.002) and total hip (p = 0.038). At the 12-month stage, the change in the BMD percentage between the 2 groups was statistically significantly different at the lumber (p = 0.038). And each difference made out that the risedronate group was preserving BMD. In urinary NTX, bone turn over was statistically significantly decreased with the risedronate group compared with the control group at the 12-month stage (p = 0.017).
  
  
  CONCLUSIONS
  We assure the beginning of bone loss at an early date (6 months) with ADT. Daily oral risedronate in patients with receiving ADT reduces bone mineral loss and maintain BMD.
authors.affiliation: Department of Urology, Kitasato University of Medicine.
authors.forename: Masaki
authors.initials: M
authors.lastname: Kimura
authors.forename: Takefumi
authors.initials: T
authors.lastname: Satoh
authors.forename: Miyoko
authors.initials: M
authors.lastname: Okazaki
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Tabata
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tsuboi
authors.forename: Toru
authors.initials: T
authors.lastname: Hyodo
authors.forename: Eiji
authors.initials: E
authors.lastname: Yokoyama
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Shigehiro
authors.initials: S
authors.lastname: Soh
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Iwamura
authors.forename: Kazushige
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Shiro
authors.initials: S
authors.lastname: Bab
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology* / Q000517:prevention & control*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D000068296:Risedronic Acid
chemical_list: D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid